EUVIMEDEUVIMED entdecken
Crossref

Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1667c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old who have stage 2 type 1 diabetes. It is the first drug to become available in the US that delays the onset of type 1 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HumansHypoglycemic AgentsAntibodies, Monoclonal, HumanizedInsulin

Stichwörter der Autor:innen

Tzieldadverse effectsdosagedrug interactionsefficacyinsulinlactationpregnancysafetyteplizumabtype 1 diabetes

Substanzen

teplizumabHypoglycemic AgentsAntibodies, Monoclonal, HumanizedInsulin

Zitieren

APA

(2023). Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1667c

Vancouver

Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1667c

BibTeX
@article{euvimed2023,
  title = {Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1667c}
}
Kostenlos starten →